The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
About The Author
The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
